ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The health-care investment firm Deerfield Management has launched a biotech start-up called Civetta Therapeutics with $53 million in series A financing. Civetta will develop small molecules that target β propeller proteins, which get their name from β-pleated amino acid sheets arranged in a circle like a propeller or pinwheel. The Cambridge, Massachusetts–based firm says β propeller proteins are important for protein-protein interactions and are implicated in cancer, metabolic diseases, and neurodegeneration.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter